AMGEN Inc

NASDAQ: AMGN
$280.07
+$0.06 (+0.0%)
Closing Price on November 27, 2024

AMGN Articles

Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
The top analyst upgrades, downgrades and other research calls from Wednesday include Abercrombie & Fitch, Amgen, Electronic Arts, General Motors, Goldcorp, Shopify, 3D Systems and Under Armour.
The October 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
The September 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
CytomX Therapeutics shares made a solid gain in Wednesday’s session following announcement of a strategic collaboration with Amgen in immuno-oncology.
AbbVie shares made a handy gain on Thursday after it was announced that the company resolved its Humira patent disputes with Amgen.
The September 15 short interest data have been compared with the previous report, and short interest in all the selected biotech stocks increased.
The August 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
The August 15 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
The July 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The July 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The June 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The biotech industry has made a splash in 2017, outperforming practically all the broad markets. With this incredible display, it's no wonder that investor interest in this particular industry has...